Recent advances in understanding of pathogenesis and treatment development for diffuse large B-cell lymphoma and follicular lymphoma

No abstract is available for this paper.

• Publication year

  2025

• Venue

  International journal of hematology

• Publication date

  2025-02-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12185-025-03939-9PMID 39928216
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

  2022cited by this paper
• Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

  2022cited by this paper
• Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.

  2021cited by this paper
• Diffuse Large B-Cell Lymphoma.

  2021cited by this paper
• Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

  2021cited by this paper
• A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.

  2020cited by this paper
• Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

  2020cited by this paper
• Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma.

  2020cited by this paper
• TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma

  2020cited by this paper
• Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.

  2019cited by this paper
• Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma

  2018cited by this paper
• Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

  2018cited by this paper
• Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study

  2016cited by this paper
• The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

  2016cited by this paper
• Germinal centres and B cell lymphomagenesis

  2015cited by this paper
• Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

  2015cited by this paper
• Diffuse large B-cell lymphoma—treatment approaches in the molecular era

  2014cited by this paper
• Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma

  2013cited by this paper
• Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

  2012cited by this paper
• Frequent mutation of histone modifying genes in non-Hodgkin lymphoma

  2011cited by this paper
• Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma

  2011cited by this paper
• Diffuse large B-cell lymphoma.

  2007cited by this paper
• Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.

  2005cited by this paper
• Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

  2004cited by this paper
• Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

  2002cited by this paper
• The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

  2002cited by this paper
• Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

  2000cited by this paper

• No citing papers are available for this paper.